Form 4: Nurix CFO Sells Shares Under Pre-Arranged Trading Plan

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold 5,402 shares of common stock at a weighted average price of $11.0325 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NRIX), reported a sale of common stock.
• The transaction involved the disposition of 5,402 shares.
• The shares were sold at a weighted average price of $11.0325 per share.
• The sale price ranged from a low of $10.88 to a high of $11.21.
• Following this transaction, Hans van Houte directly beneficially owns 35,512 shares of Nurix Therapeutics common stock.
• The transaction was executed pursuant to a pre-adopted Rule 10b5-1 trading plan.
• The reported transaction date is August 1, 2025.

Sentiment

Score: 5

Explanation: The sale of shares by the CFO, while a disposition, was conducted under a pre-arranged Rule 10b5-1 trading plan, which mitigates the negative perception typically associated with insider selling. It suggests a planned liquidity event rather than a reaction to adverse company news.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale and not a reaction to recent company developments.

Negatives

• Chief Financial Officer Hans van Houte sold 5,402 shares of common stock.
• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted as a lack of confidence in future stock price appreciation, though this is mitigated by the pre-arranged nature.

Risks

• Potential negative market perception due to insider share disposition, despite the Rule 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some may see it as a planned event (due to 10b5-1), others as a potential lack of confidence.

Key Dates

Recommendation

The transaction is a pre-planned sale by an insider under a Rule 10b5-1 plan, which is a routine event for liquidity management and does not necessarily signal a change in the company's fundamental outlook. While insider selling can sometimes be viewed negatively, the pre-arranged nature mitigates this concern. Therefore, the filing itself does not provide a strong basis for a "buy" or "sell" recommendation, suggesting a "hold" position is appropriate based solely on this specific disclosure.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Trading, Share Sale, Hans van Houte, Chief Financial Officer, 10b5-1 Plan, Stock Transaction